Table II. Outcomes.

Diagnosis	Good CR*†	CR	CRi	Refractory	TRM*	Relapse	HCT
All patients (24)	12 (50%)	15 (63%)	2 (8%)	5 (21%)	2 (8%)	5 (21%)	11 (46%)
AML (21); n (%)	10 (48%)	13 (62%)	1 (5%)	5 (24%)	2 (9%)	4 (19%)	9 (43%)
Risk groups‡
Favorable (4)	3	0	0	0	1	0	0
Intermediate-I (4)	3	1	0	0	0	1	3
Intermediate-II (6)	2	1	1	1	1	2	2
Adverse (7)	2	1	0	4	0	3	4
MDS (2)	2 (100%)	2(100%)		0	0	1 (50%)	1 (50%)
CMML (1)	0	0	1 (100%)	0	0	0	1 (100%)

^*Primary study endpoints ;

^†CR without evidence of MRD ;

^‡per ELN criteria ; MRD: minimal residual disease, TRM: treatment-related mortality, HCT: hematopoietic stem cell transplantation